


Technology Advisory Committee A Interests Register Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

Publication Date: 21/07/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Mr Dominic Pivonka	TA Committee A Member	Direct financial interests	Mr Pivonka's employer, AbbVie, is a comparator company (adalimumab) for this treatment, and has another treatment recently licensed for ankylosing spondylitis, upadacitinib.	NA	09/02/2021	NA	It was agreed that this declaration would prevent Mr Pivonka from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
Professor Abdallah Al- Mohammed	TA Committee A Member	Direct financial interests	Attended advisory board with Novartis in October 2019, related to publication of the PARAGON study. This study was in an unrelated disease area. Also received honoraria in July 2020, to give a presentation to Novartis staff on heart failure.	NA	06/05/2021	NA	It was agreed that these declarations would not prevent Professor Al-Mohammad from participating in this section of the meeting.
Dr Helena Marzo- Ortega	Clinical expert	Direct financial interests	Received research grants from Janssen and Novartis. Received speaker fees/consultancy fees/honoraria from Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Takeda and UCB.	NA	20/01/2020	NA	It was agreed that these declarations would not prevent Dr Marzo-Ortega from providing expert advice to the committee.



Dr Helena Marzo- Ortega	Clinical expert	Direct financial interests	Partook in medical advisory boards with Eli Lilly in April 2019, November 2019 and December 2020, as well as being a speaker at EULAR Symposium in June 2020, which was supported by Eli Lilly.	NA	16/02/2021	NA	It was agreed that these declarations would not prevent Dr Marzo-Ortega from providing expert advice to the committee.
Dr Louise Warburton	Clinical expert	Direct financial interests	Partook in a webinar talk for MIMS Live on Osteoporosis which was pharma sponsored in November 2020.	NA	18/02/2021	NA	It was agreed that this declaration would not prevent Dr Warburton from providing expert advice to the committee.
Dr Louise Warburton	Clinical expert	Direct non- financial interests	Dr Warburton is a NICE fellow and is on the Executive Committee of the Primary Care Rheumatology and MSK Medicine Society, supported by pharma.	NA	18/02/2021	NA	It was agreed that these declarations would not prevent Dr Warburton from providing expert advice to the committee.